Please assess the completion status of the following clinical trial:

Trial Title: Trial of Adoptive T Cell Therapy With Activated P53 Specific T Cells for Treatment of Advanced Colorectal Cancer

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE1
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria~* Histologically confirmed UICC stage IV colorectal cancer and non resectable primary tumor and/or metastases~* Previous palliative standard systemic treatment with FOLFOX, FOLFIRI, or FOLFIRINOX in combination with Bevacizumab or Cetuximab/Panitumumab, and currently under respective treatment~* The following situation after at least four cycles with FOLFOX, FOLFIRI, or FOLFIRINOX in combination with Bevacizumab or Cetuximab/Panitumumab should apply:~  * Disease control (stable disease, partial response or complete response) according routine imaging~ * Resection of tumor and/or metastases still impossible~ * Tolerability of systemic treatment~ * The decision of the treating physician is to continue the standard background treatment~* Presence of tumor-reactive T cells in the blood as detected by ex vivo IFN-γ EliSpot assay and classification of the reaction as a response in a blood sample~* ECOG-performance status 0 or 1~* Adequate vein status at both cubital fossas for 16 G puncture (white permanent venous catheter, Braunüle; EN ISO 6009)~* Age ≥ 18 years, any ethnic origin and gender~* Ability of the patient to understand the character and individual consequences of the clinical trial~* Patients should be willing and able to comply with scheduled visits, treatment plan, laboratory tests, and other study procedures~* Written informed consent (must be available before enrolment in the trial)~* Negative pregnancy test (females of childbearing potential)~* Women with childbearing potential and male patients with partners of childbearing potential should be willing to use adequate contraception (failure rate less than 1% per year when used consistently and correctly) during the study and three month last application of T cell therapy~* At the screening visit the following laboratory parameters apply and should be within the ranges specified:~Lab Parameter Range WBC ≥4000/mm3 (≥4000/ul) Platelets ≥80.000/mm3 (≥80.000/ul) Creatinine ≤1.5mg/dl ALT, AST, and total bilirubin \< 2.5 x ULN HB\* \> 9 g/dl~\*HB is controlled again at day -11 at DRK Mannheim as part of the procedures before leukapheris.~Exclusion Criteria~* Brain or leptomeningeal metastases, shown by MRI Scan during Screening phase or by routinely available other appropriate diagnostic (CT, MRI, PET) conducted within 3 months prior to inclusion.~* Previous malignancy within the past 5 years. However: Patients who had curatively treated basal cell carcinoma of the skin, early gastrointestinal cancer treated by endoscopic resection and/or in situ carcinoma of the cervix are allowed for enrolment.~* History of organ allograft or prior hematopoetic stem cell transplantation~* History of inflammatory bowel disease (ulcerative colitis, Crohn's disease)~* History of symptomatic autoimmune disease (e.g., rheumatoid arthritis, systemic progressive sclerosis \[scleroderma\], systemic lupus erythematosus, autoimmune vasculitis \[e.g., Wegener's Granulomatosis\])~* History of motor neuropathy considered of autoimmune origin (e.g., Guillain-Barré Syndrome)~* Clinically significant cardiac disease (NYHA Class III or IV).~* Other serious illnesses, which renders the patient unsuitable for study entry or multiple blood sampling~* Serious intercurrent illness, requiring hospitalization~* HIV and/or HBC/HCV positivity, tested by appropriate infection diagnostics during screening period~* Any active infection or signs or symptoms of infection~* Patient pregnant or breastfeeding~* History of hypersensitivity to the investigational medicinal product or to any excipient present in the investigational medicinal product or to anti-coagulance auxiliary medicianal product (Heparin prophylaxis)~* Treatment with immunosuppressive drugs (e.g. systemic corticosteroids) besides intermittent, anti-emetic steroid application during treatment with FOLFOX, FOLFIRI, or FOLFIRINOX in combination with Bevacizumab or Cetuximab/Panitumumab. Topical or inhalation steroids are permitted.~* Treatment with any approved anti-cancer therapy within 28 days prior to enrolment, except the background treatment FOLFOX, FOLFIRI, or FOLFIRINOX in combination with Bevacizumab or Cetuximab/Panitumumab.as recommended by that trial protocol~* Treatment with any live attenuated vaccine within 4 weeks before first administration of investigational medicinal product~* Treatment with any other investigational agent or participation in another interventional clinical trial within 28 days prior to enrolment.~No patient will be allowed to enroll in this trial more than once.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- re-activated T cells (Type: EXPERIMENTAL): Ten patients with CRC stage UICC IV under routine first line FOLFOX 6/Bevacizumab therapy are planned to receive a singular treatment with an autologous T cell product at a dose of 5x10\^7 (first three or six patients) or 5x10\^8 (last four or seven patients) cells.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: feasibility